Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD

NCT07222553 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Immunoglobulin G4-related Disease

Interventions

DRUG: Inebilizumab

Sponsor

Amgen